TRULICITY 1.5MG/0.5ML INJ

Distributor inventory | Injection

Treatment of type 2 diabetes mellitus in adults as an adjunct to diet and exercise to improve glycaemic control; may be used alone or with other antidiabetic medicines. Also used to reduce risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors (as per prescribing information).

Dulaglutide is a GLP-1 receptor agonist that increases glucose-dependent insulin secretion and lowers inappropriate glucagon release. It also slows gastric emptying and helps reduce appetite, leading to improved blood sugar control and weight reduction in many patients.

For subcutaneous use only (abdomen, thigh, or upper arm). Usually injected once weekly, on the same day each week, with or without food; rotate injection sites and do not inject into a vein or muscle. If a dose is missed, take it within 3 days (72 hours) of the missed dose; otherwise skip and take the next dose on the regular day (follow doctor’s advice).

Nausea, vomiting, diarrhoea, abdominal pain, decreased appetite, indigestion, constipation, injection site reactions, headache, fatigue

Not for type 1 diabetes or treatment of diabetic ketoacidosis. Risk of pancreatitis—seek urgent care for severe persistent abdominal pain (with/without vomiting). May cause hypoglycaemia when used with insulin or sulfonylureas—dose adjustments may be needed. Use caution in severe gastrointestinal disease (e.g., gastroparesis). Possible risk of thyroid C-cell tumors; avoid in patients with personal/family history of medullary thyroid carcinoma or MEN2 (per class warning). Monitor renal function if severe vomiting/diarrhoea occurs (risk of dehydration and worsening kidney function).